ADRB3 and neoplasm: Mechanistically, in NB tumour-bearing mice treated with β3-AR antagonists, tumour-infiltrating lymphocytes reduced IFN-γ secretion, and this also limited their ability to trigger PD-L1 expression by NB cells [7].